313 related articles for article (PubMed ID: 18607872)
21. Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer.
Mukai H; Katsumata N; Ando M; Watanabe T
Am J Clin Oncol; 2010 Feb; 33(1):32-5. PubMed ID: 19786850
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer.
Jiang L; Wang DY; Zhu ZH; Tang LF; Hou XH; Zhao HD; Xie Z; Wang DF
Cancer Chemother Pharmacol; 2010 Aug; 66(3):449-53. PubMed ID: 19937029
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel and carboplatin in inoperable non-small cell lung cancer.
Kosmidis P; Mylonakis N; Fountzilas G; Samantas E; Athanasiadis A; Skarlos D
Semin Oncol; 1996 Dec; 23(6 Suppl 16):68-70. PubMed ID: 9007126
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?
Pentheroudakis G; Briasoulis E; Karavassilis V; Fountzilas G; Xeros N; Samelis G; Samantas E; Pavlidis N
Acta Oncol; 2005; 44(2):155-60. PubMed ID: 15788295
[TBL] [Abstract][Full Text] [Related]
25. A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer.
Giannakakis T; Kakolyris S; Theodoropoulos E; Kouroussis C; Michailakis E; Papadouris S; Tsitoura M; Kalbakis K; Souglakos J; Agelaki S; Vardakis N; Georgoulias V
Anticancer Res; 2002; 22(6B):3743-8. PubMed ID: 12552987
[TBL] [Abstract][Full Text] [Related]
26. Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer.
Brown JV; Rettenmaier MA; Dillman RA; Birk CL; Culkin K; Micha JP
Gynecol Oncol; 1998 Feb; 68(2):166-8. PubMed ID: 9514805
[TBL] [Abstract][Full Text] [Related]
27. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
28. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
[TBL] [Abstract][Full Text] [Related]
31. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
Nugent FW; Mertens WC; Graziano S; Levitan N; Collea R; Gajra A; Marshall J; McCann J
Lung Cancer; 2005 May; 48(2):267-73. PubMed ID: 15829328
[TBL] [Abstract][Full Text] [Related]
33. A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status.
Johnson FM; Garden A; Palmer JL; Kies M; Clayman G; Brumfield B; Khuri FR; Morrison W; Papadimitrakopoulou V; Diaz EM; Glisson BS
Cancer; 2004 Mar; 100(5):991-8. PubMed ID: 14983495
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer.
Sehouli J; Alvarez AM; Manouchehrpour S; Ghatage P; Szczylik C; Zimmermann A; Bauknecht T; Look KY; Oskay-Öezcelik G
Gynecol Oncol; 2012 Feb; 124(2):205-9. PubMed ID: 22044606
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group.
Vaughn DJ; Manola J; Dreicer R; See W; Levitt R; Wilding G
Cancer; 2002 Sep; 95(5):1022-7. PubMed ID: 12209686
[TBL] [Abstract][Full Text] [Related]
36. Carcinoma of unknown primary site.
Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
[TBL] [Abstract][Full Text] [Related]
37. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC.
Wachters FM; van Putten JW; Boezen HM; Groen HJ
Lung Cancer; 2004 Aug; 45(2):255-62. PubMed ID: 15246198
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
